Photodynamic therapy of malignant brain tumours: A complementary approach to conventional therapies

Cancer Treatment Reviews

Volumn 40, Issue 2, 2014, Pages 229-241

  Bechet, Denise ^a   Mordon, Serge R ^b,c   Guillemin, François ^a,c   Barberi Heyob, Muriel A ^a,c  

^a UNIVERSITÉ DE LORRAINE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c GDR 3049 Médicaments Photoactivables Photochimiothérapie PHOTOMED   (France)

Author keywords

Brain tumors; Clinical; Fluorescence guided resection; Interventional MRI; Nanoparticles; Photodynamic therapy; Pre clinical

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; BUTHIONINE SULFOXIMINE; CHLOROALUMINUM PHTHALOCYANINE; GLIAL FIBRILLARY ACIDIC PROTEIN; HEMATOPORPHYRIN DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODIES OX26; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; NANOPARTICLE; NEUROPILIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOTOFRIN; PHTHALOCYANINE; PHTHALOCYANINE PC 4; PROTOPORPHYRIN; ROSTAPORFIN; SINGLET OXYGEN; TALAPORFIN; TEMOPORFIN; TEMOZOLOMIDE; TETRAKIS(3 HYDROXYPHENYL)CHLORIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VERTEPORFIN; VISUDINE; VON WILLEBRAND FACTOR;

ANTIANGIOGENIC THERAPY; APOPTOSIS; BLOOD BRAIN BARRIER; BRACHYTHERAPY; BRAIN CANCER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CONTRAST ENHANCEMENT; CYTOREDUCTIVE SURGERY; DOSIMETRY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; EPENDYMOMA; FLUORESCENCE GUIDED RESECTION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; HYPERTHERMIC THERAPY; HYPOPHYSIS ADENOMA; INTENSITY MODULATED RADIATION THERAPY; INTERSTITIAL PHOTODYNAMIC THERAPY; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; LOCAL THERAPY; MALIGNANT MENINGIOMA; MULTIMODALITY CANCER THERAPY; NANOBIOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PEROPERATIVE CARE; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIOSURGERY; RECURRENT CANCER; REVIEW; SURVIVAL TIME; TREATMENT PLANNING; TUMOR INVASION;

BRAIN TUMORS; CLINICAL; FLUORESCENCE-GUIDED RESECTION; INTERVENTIONAL MRI; NANOPARTICLES; PHOTODYNAMIC THERAPY; PRE-CLINICAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LIGHT; NANOPARTICLES; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; RADIOSURGERY; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE;

EID: 84888308591     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.07.004     Document Type: Review

References (89)

1. Eljamel M.S. Brain photodiagnosis (PD), fluorescence guided resection (FGR) and photodynamic therapy (PDT): past, present and future. Photodiagn Photodyn Ther 2008, 5:29-35.
2. Zimmermann A., Ritsch-Marte M., Kostron H. MTHPC-mediated photodynamic diagnosis of malignant brain tumors. Photochem Photobiol 2001, 74:611-616.
3. Eljamel M.S. Brain PDD and PDT unlocking the mystery of malignant gliomas. Photodiagn Photodyn Ther 2004, 1:303-310.
4. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006, 7:392-401.
5. Eljamel M.S., Goodman C., Moseley H. ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. Lasers Med Sci 2008, 23:361-367.
6. Stepp H., Beck T., Pongratz T., Meinel T., Kreth F.W., Tonn J., et al. ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment. J Environ Pathol Toxicol Oncol 2007, 26:157-164.
7. Aziz F., Telara S., Moseley H., Goodman C., Manthri P., Eljamel M.S. Photodynamic therapy adjuvant to surgery in metastatic carcinoma in brain. Photodiagn Photodyn Ther 2009, 6:227-230.
8. Zilidis G., Aziz F., Telara S., Eljamel M.S. Fluorescence image-guided surgery and repetitive Photodynamic Therapy in brain metastatic malignant melanoma. Photodiagn Photodyn Ther 2008, 5:264-266.
9. Stylli S.S., Kaye A.H., MacGregor L., Howes M., Rajendra P. Photodynamic therapy of high grade glioma - long term survival. J Clin Neurosci 2005, 12:389-398.
10. Varma A.K., Muller P.J. Cranial neuropathies after intracranial Photofrin-photodynamic therapy for malignant supratentorial gliomas - a report on 3 cases. Surg Neurol 2008, 70:190-193.
11. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
12. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
13. Kostron H., Swartz M.R., Miller D.C., Martuza R.L. The interaction of hematoporphyrin derivative, light, and ionizing radiation in a rat glioma model. Cancer 1986, 57:964-970.
14. Kostron H., Fiegele T., Akatuna E. Combination of FOSCAN ® mediated fluorescence guided resection and photodynamic treatment as new therapeutic concept for malignant brain tumors. Med Laser Appl 2006, 21:285-290.
15. Kaye A.H., Morstyn G., Brownbill D. Adjuvant high-dose photoradiation therapy in the treatment of cerebral glioma: a phase 1-2 study. J Neurosurg 1987, 67:500-505.
16. Hirschberg H., Sun C.H., Tromberg B.J., Yeh A.T., Madsen S.J. Enhanced cytotoxic effects of 5-aminolevulinic acid-mediated photodynamic therapy by concurrent hyperthermia in glioma spheroids. J Neurooncol 2004, 70:289-299.
17. Krishnamurthy S., Powers S.K., Witmer P., Brown T. Optimal light dose for interstitial photodynamic therapy in treatment for malignant brain tumors. Lasers Surg Med 2000, 27:224-234.
18. Kostron H., Obwegeser A., Jakober R. Photodynamic therapy in neurosurgery: a review. J Photochem Photobiol B 1996, 36:157-168.
19. Marks P.V., Belchetz P.E., Saxena A., Igbaseimokumo U., Thomson S., Nelson M., et al. Effect of photodynamic therapy on recurrent pituitary adenomas: clinical phase I/II trial - an early report. Br J Neurosurg 2000, 14:317-325.
20. Powers S.K., Cush S.S., Walstad D.L., Kwock L. Stereotactic intratumoral photodynamic therapy for recurrent malignant brain tumors. Neurosurgery 1991, 29:688-695. discussion 695-6.
21. Muller P.J., Wilson B.C. Photodynamic therapy of brain tumors - a work in progress. Lasers Surg Med 2006, 38:384-389.
22. Raskopf E., Vogt A., Standop J., Sauerbruch T., Schmitz V. Inhibition of neuropilin-1 by RNA-interference and its angiostatic potential in the treatment of hepatocellular carcinoma. Z Gastroenterol 2010, 48:21-27.
23. Rosenthal M.A., Kavar B., Hill J.S., Morgan D.J., Nation R.L., Stylli S.S., et al. Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin. J Clin Oncol 2001, 19:519-524.
24. Sreenivasan R., Muruganandham M., Sharma M., Joshi P.G., Joshi N.B. Binding of monomeric and oligomeric porphyrins to human glioblastoma (U-87MG) cells and their photosensitivity. Cancer Lett 1997, 120:45-51.
25. Chopp M., Dereski M.O., Madigan L., Jiang F., Logie B. Sensitivity of 9L gliosarcomas to photodynamic therapy. Radiat Res 1996, 146:461-465.
26. Chopp M., Madigan L., Dereski M., Jiang F., Li Y. Photodynamic therapy of human glioma (U87) in the nude rat. Photochem Photobiol 1996, 64:707-711.
27. Johansson A., Palte G., Schnell O., Tonn J.C., Herms J., Stepp H. 5-Aminolevulinic acid-induced protoporphyrin IX levels in tissue of human malignant brain tumors. Photochem Photobiol 2010, 86:1373-1378.
28. Wilson B.C., Patterson M.S., Lilge L. Implicit and explicit dosimetry in photodynamic therapy: a new paradigm. Lasers Med Sci 1997, 12:182-199.
29. Ascencio M., Collinet P., Farine M.O., Mordon S. Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy. Lasers Surg Med 2008, 40:332-341.
30. Haj-Hosseini N., Richter J., Andersson-Engels S., Wardell K. Optical touch pointer for fluorescence guided glioblastoma resection using 5-aminolevulinic acid. Lasers Surg Med 2010, 42:9-14.
31. Robinson D.J., de Bruijn H.S., van der Veen N., Stringer M.R., Brown S.B., Star W.M. Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and irradiance and the resulting biological effect. Photochem Photobiol 1998, 67:140-149.
32. Muller P.J., Wilson B.C. Photodynamic therapy of malignant primary brain tumours: clinical effects, post-operative ICP, and light penetration of the brain. Photochem Photobiol 1987, 46:929-935.
33. Muller P.J., Wilson B.C. Photodynamic therapy for recurrent supratentorial gliomas. Semin Surg Oncol 1995, 11:346-354.
34. Muller P.J., Wilson B.C. Photodynamic therapy for malignant newly diagnosed supratentorial gliomas. J Clin Laser Med Surg 1996, 14:263-270.
35. Muller P.J., Wilson B.C. An update on the penetration depth of 630nm light in normal and malignant human brain tissue in vivo. Phys Med Biol 1986, 31:1295-1297.
36. Henderson B.W., Busch T.M., Vaughan L.A., Frawley N.P., Babich D., Sosa T.A., et al. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res 2000, 60:525-529.
37. Madsen S.J., Angell-Petersen E., Spetalen S., Carper S.W., Ziegler S.A., Hirschberg H. Photodynamic therapy of newly implanted glioma cells in the rat brain. Lasers Surg Med 2006, 38:540-548.
38. Ascencio M., Estevez J.P., Delemer M., Farine M.O., Collinet P., Mordon S. Comparison of continuous and fractionated illumination during hexaminolaevulinate-photodynamic therapy. Photodiagn Photodyn Ther 2008, 5:210-216.
39. Estevez J.P., Ascencio M., Colin P., Farine M.O., Collinet P., Mordon S. Continuous or fractionated photodynamic therapy? Comparison of three PDT schemes for ovarian peritoneal micrometastasis treatment in a rat model. Photodiagn Photodyn Ther 2008, 7:251-257.
40. Curnow A., McIlroy B.W., Postle-Hacon M.J., MacRobert A.J., Bown S.G. Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon. Photochem Photobiol 1999, 69:71-76.
41. Bogaards A., Varma A., Zhang K., Zach D., Bisland S.K., Moriyama E.H., et al. Fluorescence image-guided brain tumour resection with adjuvant metronomic photodynamic therapy: pre-clinical model and technology development. Photochem Photobiol Sci 2005, 4:438-442.
42. Bisland S.K., Lilge L., Lin A., Rusnov R., Wilson B.C. Metronomic photodynamic therapy as a new paradigm for photodynamic therapy: rationale and preclinical evaluation of technical feasibility for treating malignant brain tumors. Photochem Photobiol 2004, 80:22-30.
43. van Zaane F., Subbaiyan D., van der Ploeg-van A., den Heuvel H.S., de Bruijn E.M., et al. A telemetric light delivery system for metronomic photodynamic therapy (mPDT) in rats. J Biophotonics 2010, 3:347-355.
44. Finlay J.C., Foster T.H. Hemoglobin oxygen saturations in phantoms and in vivo from measurements of steady-state diffuse reflectance at a single, short source-detector separation. Med Phys 2004, 31:1949-1959.
45. Cheong W.F., Prahl S.A., Welch A.J. A review of the optical properties of biological tissues. IEEE J Quantum Electron 1990, 26.
46. Angell-Petersen E., Hirschberg H., Madsen S.J. Determination of fluence rate and temperature distributions in the rat brain; implications for photodynamic therapy. J Biomed Opt 2007, 12:014003.
47. Angell-Petersen E., Spetalen S., Madsen S.J., Sun C.H., Peng Q., Carper S.W., et al. Influence of light fluence rate on the effects of photodynamic therapy in an orthotopic rat glioma model. J Neurosurg 2006, 104:109-117.
48. Eggert H.R., Blazek V. Optical properties of human brain tissue, meninges, and brain tumors in the spectral range of 200 to 900nm. Neurosurgery 1987, 21:459-464.
49. Origitanoand T.C., Reichman O.H. Photodynamic therapy for intracranial neoplasms: development of an image-based computer-assisted protocol for photodynamic therapy of intracranial neoplasms. Neurosurgery 1993, 32:587-595. discussion 595-6.
50. Origitano T.C., Karesh S.M., Henkin R.E., Halama J.R., Reichman O.H. Photodynamic therapy for intracranial neoplasms: investigations of photosensitizer uptake and distribution using indium-111 Photofrin-II single photon emission computed tomography scans in humans with intracranial neoplasms. Neurosurgery 1993, 32:357-363. discussion 363-4.
51. Beck T.J., Kreth F.W., Beyer W., Mehrkens J.H., Obermeier A., Stepp H., et al. Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg Med 2007, 39:386-393.
52. Kostron H., Zimmermann A., Obwegeser A. MTHPC-mediated photodynamic detection for fluorescence-guided resection of brain tumors. Proc SPIE 1998, 3262:259-264.
53. Yang V.X., Muller P.J., Herman P., Wilson B.C. A multispectral fluorescence imaging system: design and initial clinical tests in intra-operative Photofrin-photodynamic therapy of brain tumors. Lasers Surg Med 2003, 32:224-232.
54. Richter J.C., Haj-Hosseini N., Andersson-Engel S., Wardell K. Fluorescence spectroscopy measurements in ultrasonic navigated resection of malignant brain tumors. Lasers Surg Med 2011, 43:8-14.
55. Powers S.K., Brown J.T. Light dosimetry in brain tissue: an in vivo model applicable to photodynamic therapy. Lasers Surg Med 1986, 6:318-322.
56. Tudge S.H., Kaye A.H., Hill J.S. Modulation of light delivery in photodynamic therapy of brain tumours. J Clin Neurosci 1999, 6:227-232.
57. Hirschberg H., Spetalen S., Carper S., Hole P., Tillung T., Madsen S. Minimally invasive photodynamic therapy (PDT) for ablation of experimental rat glioma. Minim Invasive Neurosurg 2006, 49:135-142.
58. Olzowy B., Hundt C.S., Stocker S., Bise K., Reulen H.J., Stummer W. Photoirradiation therapy of experimental malignant glioma with 5-aminolevulinic acid. J Neurosurg 2002, 97:970-976.
59. George J.E., Ahmad Y., Varghai D., Li X., Berlin J., Jackowe D., et al. Pc 4 photodynamic therapy of U87-derived human glioma in the nude rat. Lasers Surg Med 2005, 36:383-389.
60. Namatame H., Akimoto J., Matsumura H., Haraoka J., Aizawa K. Photodynamic therapy of C6-implanted glioma cells in the rat brain employing second-generation photosensitizer talaporfin sodium. Photodiagn Photodyn Ther 2008, 5:198-209.
61. Olivier D., Bourre L., El-Sabbagh E., Loussouarn D., Simonneaux G., Valette F., et al. Photodynamic effects of SIM01, a new sensitizer, on experimental brain tumors in rats. Surg Neurol 2007, 68:255-263. discussion 263.
62. Lilge L., Portnoy M., Wilson B.C. Apoptosis induced in vivo by photodynamic therapy in normal brain and intracranial tumour tissue. Br J Cancer 2000, 83:1110-1117.
63. Hirschberg H., Uzal F.A., Chighvinadze D., Zhang M.J., Peng Q., Madsen S.J. Disruption of the blood-brain barrier following ALA-mediated photodynamic therapy. Lasers Surg Med 2008, 40:535-542.
64. Goetz C., Hasan A., Stummer W., Heimann A., Kempski O. Experimental research photodynamic effects in perifocal, oedematous brain tissue. Acta Neurochir (Wien) 2002, 144:173-179. discussion 179.
65. Li F., Zhu G., Lin J., Meng H., Wu N., Du Y., et al. Photodynamic therapy increases brain edema and intracranial pressure in a rabbit brain tumor model. Acta Neurochir 2006, 96:422-425.
66. Jiang F., Zhang Z.G., Katakowski M., Robin A.M., Faber M., Zhang F., et al. Angiogenesis induced by photodynamic therapy in normal rat brains. Photochem Photobiol 2004, 79:494-498.
67. Zhang X., Jiang F., Kalkanis S.N., Zhang Z., Hong X., Yang H., et al. Post-acute response of 9L gliosarcoma to Photofrin-mediated PDT in athymic nude mice. Lasers Med Sci 2007, 22:253-259.
68. Jiang F., Zhang X., Kalkanis S.N., Zhang Z., Yang H., Katakowski M., et al. Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma. Photochem Photobiol 2008, 84:128-137.
69. Zheng X., Jiang F., Katakowski M., Zhang X., Jiang H., Zhang Z.G., et al. Sensitization of cerebral tissue in nude mice with photodynamic therapy induces ADAM17/TACE and promotes glioma cell invasion. Cancer Lett 2008, 265:177-187.
70. deCarvalho A.C., Zhang X., Roberts C., Jiang F., Kalkanis S.N., Hong X., et al. Subclinical photodynamic therapy treatment modifies the brain microenvironment and promotes glioma growth. Glia 2007, 55:1053-1060.
71. Orive G., Ali O.A., Anitua E., Pedraz J.L., Emerich D.F. Biomaterial-based technologies for brain anti-cancer therapeutics and imaging. Biochim Biophys Acta 2010, 1806:96-107.
72. Beduneau A., Hindre F., Clavreul A., Leroux J.C., Saulnier P., Benoit J.P. Brain targeting using novel lipid nanovectors. J Controlled Release 2008, 126:44-49.
73. Beduneau A., Saulnier P., Benoit J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28:4947-4967.
74. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
75. Couleaud P., Bechet D., Vanderesse R., Barberi-Heyob M., Faure A.C., Roux S., et al. Functionalized silica-based nanoparticles for photodynamic therapy. Nanomedicine (Lond) 2011, 6:995-1009.
76. Juzenas P., Chen W., Sun Y.P., Coelho M.A., Generalov R., Generalova N., et al. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv Drug Deliv Rev 2008, 60:1600-1614.
77. Mowat P., Mignot A., Rima W., Lux F., Tillement O., Roulin C., et al. In vitro radiosensitizing effects of ultrasmall gadolinium based particles on tumour cells. J Nanosci Nanotechnol 2011, 11:7833-7839.
78. Chen W. Nanoparticle based photodynamic therapy for cancer treatment 2007, American Scientific Publishers.
79. Chenand W., Zhang J. Using nanoparticles to enable simultaneous radiation and photodynamic therapies for cancer treatment. J Nanosci Nanotechnol 2006, 6:1159-1166.
80. Sessler J.L., Miller R.A. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 2000, 59:733-739.
81. Weinstein J.S., Varallyay C.G., Dosa E., Gahramanov S., Hamilton B., Rooney W.D., et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 2010, 30:15-35.
82. Koo Y.E., Reddy G.R., Bhojani M., Schneider R., Philbert M.A., Rehemtulla A., et al. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev 2006, 58:1556-1577.
83. Reddy G.R., Bhojani M.S., McConville P., Moody J., Moffat B.A., Hall D.E., et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006, 12:6677-6686.
84. Ross B., Rehemtulla A., Koo Y.E., Reddy G.R., Gwangseong K., Behrend C., et al. Photonic and magnetic nanoexplorers for biomedical use: from subcellular imaging to cancer diagnostics and therapy 2004, SPIE, Bellingham, WA.
85. Neuwelt E.A., Varallyay P., Bago A.G., Muldoon L.L., Nesbit G., Nixon R. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol Appl Neurobiol 2004, 30:456-471.
86. Vaidya A., Sun Y., Feng Y., Emerson L., Jeong E.K., Lu Z.R. Contrast-enhanced MRI-guided photodynamic cancer therapy with a pegylated bifunctional polymer conjugate. Pharm Res 2008, 25:2002-2011.
87. Hjornevik T., Leergaard T.B., Darine D., Moldestad O., Dale A.M., Willoch F., et al. Three-dimensional atlas system for mouse and rat brain imaging data. Front Neuroinformatics 2007, 1:4.
88. Larrat B., Pernot M., Aubry J.F., Dervishi E., Sinkus R., Seilhean D., et al. MR-guided transcranial brain HIFU in small animal models. Phys Med Biol 2010, 55:365-388.
89. Kim B., Chenevert T.L., Ross B.D. Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging. Clin Cancer Res 1995, 1:643-650.